Irreversible fatty acid amide hydrolase (FAAH) inhibitor (IC50
= 16.2 nM) that displays no activity at a range of other serine hydrolases. Selectively inhibits FAAH within the central nervous system. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
Ahn et al.
Structure-guided inhibitor design for human FAAH by interspecies active site conversion.
Mileni et al.